Figure 5

Effects of the CB1 receptor antagonist SR141716A on basal extracellular DA and glutamate in the NAc. (A,B) Systemic administration of SR141716A did not alter basal extracellular DA, but significantly elevated extracellular glutamate. (C,D) Intra-NAc local perfusion of the selective CB1 antagonist SR141716A also failed to alter extracellular DA, but significantly elevated extracellular glutamate. (E,F) Intra-NAc local perfusion of SR141716A prior to MPEP failed to alter NAc DA (E), but blocked MPEP-enhanced extracellular glutamate (F). *p < 0.05, **p < 0.01, compared to pre-SR141716A baseline.